Ipca Labs Q3 Profit Jumps 31%, Margins Expand on Strong Sales Growth

• Ipca Laboratories reported a 31.5% year-on-year net profit increase to ₹326.3 crore in Q3 FY26.
• Revenue grew 6.6% to ₹2,392.5 crore, driven by robust domestic and export sales.
• EBITDA rose 15.2% to ₹533.7 crore, with margins expanding to 22.3% from 20.6%.
• Indian formulations income increased 12% to ₹984 crore, while export income grew 13% to ₹770.49 crore.
• Shares of Ipca Laboratories traded up 0.85% on the NSE following the earnings announcement.